MILFORD, Mass., July 2, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) will hold its Q2 2026 fi

Piper Sandler analyst David Westenberg initiates coverage on Waters (NYSE:WAT) with a Neutral rat

FDA 510(k)-cleared BD BACTEC™ FXI Culture System now available to U.S. market, enabling broader acce

B of A Securities analyst Derik De Bruin maintains Waters (NYSE:WAT) with a Neutral and raises th

Wolfe Research analyst Mike Polark assumes Waters (NYSE:WAT) with a Outperform rating and announc

Wells Fargo analyst Brandon Couillard maintains Waters (NYSE:WAT) with a Equal-Weight and raises

Barclays analyst Luke Sergott maintains Waters (NYSE:WAT) with a Overweight and raises the price

JP Morgan analyst Casey Woodring maintains Waters (NYSE:WAT) with a Neutral and raises the price

TD Cowen analyst Dan Brennan maintains Waters (NYSE:WAT) with a Hold and raises the price target

The Nasdaq 100 surged past 28,000 during Tuesday morning trading, setting a fresh record as AI-drive

Dow Jones up 200 points, Rockwell Automation shares rise 10.8% on strong earnings and raised guidanc

Waters (NYSE:WAT) is looking for Q2 Adj EPS of $2.95-$3.05 vs $2.98 analyst estimate. sees sales of

Waters (NYSE:WAT) reported quarterly earnings of $2.70 per share which beat the analyst consensus es

Waters shares rise after FDA clears at-home HPV test kit, boosting screening access; technicals show

FDA-approved BD Onclarity™ HPV Assay is the most comprehensive screening tool for HPV in the U.S.1,4

Top analysts change outlook for top names. Citigroup, Tigress Fin, Piper Sandler, Morgan Stanley, HC

Deutsche Bank analyst Justin Bowers maintains Waters (NYSE:WAT) with a Hold and lowers the price

 Waters Corporation (NYSE:WAT) (the "Company" or "Waters") today announced that it h

WATERS CORPORATIONCommon StockPreferred StockDebt SecuritiesGuarantees of Debt SecuritiesWarrantsSto

Morgan Stanley analyst Kallum Titchmarsh maintains Waters (NYSE:WAT) with a Equal-Weight and lowe

Wells Fargo analyst Brandon Couillard maintains Waters (NYSE:WAT) with a Equal-Weight and lowers

Becton Dickinson (BDX) reported Q1 2026 earnings above consensus and provided guidance for the year.

Software stocks extended their rebound for a second straight session after last week's brutal se

Waters Corp (WAT) reports Q4 2025 results and fiscal 2026 guidance, with sales up 7% and adjusted ea

BDX Q1 2026 adjusted earnings of $2.91/share beats consensus of $2.81. Sales of $5.25B slightly abov

BD (Becton, Dickinson and Company) (NYSE:BDX) today announced the successful completion of the previ

Waters (NYSE:WAT) reported quarterly earnings of $4.53 per share which beat the analyst consensus es

Waters Corporation (NYSE:WAT) (the "Company" or "Waters") today announced that, at t

HSBC analyst Sidharth Sahoo initiates coverage on Waters (NYSE:WAT) with a Buy rating and announc

William Blair starts coverage on Waters with an Outperform rating, saying the BD merger could drive

Wells Fargo analyst Brandon Couillard maintains Waters (NYSE:WAT) with a Equal-Weight and raises

Wolfe Research analyst Doug Schenkel upgrades Waters (NYSE:WAT) from Peer Perform to Outperform and

Morgan Stanley analyst Kallum Titchmarsh initiates coverage on Waters (NYSE:WAT) with a Equal-Wei

https://ec.europa.eu/commission/presscorner/detail/en/mex_25_2796

Becton Dickinson posts Q4 earnings beat, raises FY26 EPS outlook, with strong growth in Medical and

TD Cowen analyst Dan Brennan maintains Waters (NYSE:WAT) with a Hold and raises the price target

Wells Fargo analyst Brandon Couillard maintains Waters (NYSE:WAT) with a Equal-Weight and raises

Elevance Health and Waters led the weekly large-cap losers, hit by weak earnings, lowered guidance,